LY4336619 / Eli Lilly - LARVOL DELTA

Preclinical characterization of LY4336619, a novel ALPPL2xCD3 bispecific antibody, for the treatment of ovarian and endometrial cancer (AACR 2026) - "Additional preliminary studies revealed that the combination treatment with LY4170156, a clinical-stage anti-FRα antibody-drug conjugate (ADC), resulted in more sustained and pronounced tumor growth inhibition compared to either monotherapy alone. LY4336619 has the potential as a first-in-class medicine to treat ALPPL2-positive solid tumors, including ovarian and endometrial cancers. An IND submission is anticipated for 2026."

Bispecific • Preclinical • Endometrial Cancer • Oncology • Ovarian Cancer • Solid Tumor • ALPG • ALPL • ALPP • FOLR1